New 'Living Drug' trial targets Tough-to-Treat blood cancer
NCT ID NCT07195617
Summary
This early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy for people with relapsed or refractory multiple myeloma. The therapy involves collecting a patient's own immune cells, modifying them in a lab to target two proteins on myeloma cells, and then infusing them back into the patient. The study will enroll about 10 adults who have already tried at least three other treatments for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.